David Glover
Family Medicine · Warrensburg, MONPI 1952323370
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 392 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 16.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,271 and has fallen 97.3% since, to $34 in 2025. Among family medicine clinicians in MO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 392 payments — averaging $14.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$941
- Novo Nordisk$660
- Lilly USA, LLC$566
- AstraZeneca$458
- Pfizer$457
- Merck$397
- plus $2K from 27 others
What the payments were for
- Food & beverage$5,670100%
- Education$210%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 55 | $941 |
| Novo Nordisk | 63 | $660 |
| Lilly USA, LLC | 41 | $566 |
| AstraZeneca(2 entities) | 27 | $458 |
| Pfizer | 39 | $457 |
| Merck | 28 | $397 |
| Amgen | 22 | $335 |
| Abbott | 14 | $271 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 15 | $195 |
| Teva Pharmaceuticals USA, Inc. | 8 | $121 |
| Dexcom, Inc. | 5 | $117 |
| Boehringer Ingelheim | 7 | $114 |
| GSK | 8 | $109 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $104 |
| Eisai Inc. | 6 | $99 |
| Johnson & Johnson | 7 | $91 |
| Bayer | 5 | $81 |
| Novartis | 5 | $81 |
| Supernus Pharmaceuticals, Inc. | 5 | $79 |
| E.r. Squibb & Sons, L.L.C. | 4 | $71 |
| Sanofi-aventis U.S. LLC | 4 | $58 |
| Astellas Pharma US Inc | 3 | $50 |
| Sunovion Pharmaceuticals Inc. | 2 | $44 |
| Amarin Pharma, Inc. | 3 | $43 |
| Biohaven Pharmaceuticals, Inc. | 2 | $25 |
| Sumitomo Pharma America, Inc. | 1 | $19 |
| Agile Therapeutics, Inc. | 1 | $19 |
| Halozyme Inc | 1 | $16 |
| Genentech USA, Inc. | 1 | $15 |
| Otsuka America Pharmaceutical, Inc. | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Avanir Pharmaceuticals, Inc. | 1 | $14 |
| Ferring Pharmaceuticals Inc. | 1 | $11 |
How this compares
$5,691 in reported general payments places this provider in the 90th percentile of 2,203 family medicine providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 92 | $78,617 |
| OzempicSemaglutide | 40 | $44,166 |
| FarxigaDapagliflozin Propanediol | 30 | $38,792 |
| JardianceEmpagliflozin | 25 | $27,850 |
| Tresiba Flextouch U-200Insulin Degludec | 29 | $24,510 |
| GlyxambiEmpagliflozin/Linagliptin | 23 | $17,006 |
| JanuviaSitagliptin Phosphate | 16 | $16,216 |
| Tresiba Flextouch U-100Insulin Degludec | 22 | $16,025 |
| XareltoRivaroxaban | 20 | $13,392 |
| MyrbetriqMirabegron | 11 | $7,679 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 11 | $5,185 |
| SynthroidLevothyroxine Sodium | 43 | $3,275 |
| Pantoprazole Sodium | 279 | $3,131 |
| Duloxetine Hcl | 162 | $2,950 |
| NovologInsulin Aspart | 16 | $2,913 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $457 | $78,61792 claims |
| Novo NordiskOzempic, Novolog | $660 | $47,07956 claims |
| Boehringer IngelheimJardiance, Glyxambi | $114 | $44,85548 claims |
| AstraZenecaFarxiga | $458 | $38,79230 claims |
| MerckJanuvia | $397 | $16,21616 claims |
| Johnson & JohnsonXarelto | $91 | $13,39220 claims |
| Astellas Pharma US IncMyrbetriq | $50 | $7,67911 claims |
| GSKAnoro Ellipta | $109 | $5,18511 claims |
| AbbVieSynthroid | $941 | $3,27543 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,203 family medicine providers in Missouri.
Other family medicine in Warrensburg
- Stephen AdamsSpringfield$636K
- Justin PuckettKirksville$568K
- Matthew BeckerditeOfallon$225K
- Roger CadySpringfield$175K
- James LasalleExcelsior Springs$130K
- Matthew TiefenbrunnSullivan$105K
- Ayobami OduwoleGrandview$92K
- Michael DonovanSaint Louis$78K
- Blair ThedingerKansas City$71K
- Christine MooreRaymore$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.